GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Operating Expenses | 12,422 | 14,364 | 13,576 | 21,257 | 57,515 |
| Operating Income | -12,422 | -14,364 | -13,576 | -21,257 | -57,515 |
| Interest Expense | 127 | 0 | 213 | 8 | 718 |
| Other Income | -15,805 | 1,202 | 6,192 | 381 | 220 |
| Pre-tax Income | -28,354 | -13,162 | -7,597 | -20,884 | -58,013 |
| Net Income Continuous | -28,354 | -13,162 | -7,597 | -20,884 | -58,013 |
| Net Income | $-28,354 | $-13,162 | $-7,597 | $-20,884 | $-58,013 |
| EPS Basic Total Ops | -6.68 | -6.94 | -5.64 | -19.66 | -61.86 |
| EPS Basic Continuous Ops | -5.14 | -6.94 | -5.64 | -19.66 | -61.88 |
| EPS Diluted Total Ops | -6.68 | -6.94 | -5.64 | -19.66 | -61.86 |
| EPS Diluted Continuous Ops | -5.14 | -6.94 | -5.64 | -19.66 | -61.88 |
| EPS Diluted Before Non-Recurring Items | -1.47 | -6.94 | -5.64 | -19.82 | -61.86 |
| EBITDA(a) | $-12,422 | $-14,364 | $-13,576 | $-21,257 | $-57,515 |